



OraSure Technologies, Inc.

diagnostic solutions for the new millennium

OraSure Technologies, Inc. Corporate Fact Sheet

Headquarters:

220 East First Street
Bethlehem, PA 18015
Telephone: 610-882-1820
Fax: 610-882-1825

Web site:

www.orasure.com

Stock symbol:

NASDAQ: OSUR

Management Team:

Douglas A. Michels, President and Chief Executive Officer
Ronald H. Spair, Executive Vice President and Chief Financial Officer
Stephen R. Lee, Executive Vice President and Chief Science Officer
Joseph E. Zack, Executive Vice President, Marketing and Sales
P. Michael Formica, Executive Vice President, Operations
Jack E. Jerrett, Senior Vice President and General Counsel
Sue Sutton-Jones, Senior Vice President, Regulatory Affairs and Quality Assurance
Mark Kirtland, Senior Vice President, Business Development
Mark L. Kuna, Vice President and Controller

Company Overview:

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other *in vitro* diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure's cryosurgical wart removal system is also sold into the retail or over-the-counter market in the United States and abroad.

OraSure Technologies is the leading supplier of oral fluid collection devices and assays to the life insurance industry and public health markets for the detection of antibodies to HIV. In addition, the Company supplies oral-fluid testing solutions for drugs of abuse testing.

Products:

OraSure Technologies' current products include:

Oral Fluid Testing Products

- OraQuick® *ADVANCE™* Rapid HIV-1/2 Antibody Test – the first and only FDA approved, CLIA waived, rapid point-of-care test that can detect antibodies to both HIV-1 and HIV-2 with greater than 99% accuracy in as little as 20 minutes, using an oral fluid, finger-stick or venipuncture whole blood, or plasma samples.
- OraSure® HIV-1 Oral Fluid Specimen Collection Device – the only FDA approved, laboratory-based collection device that collects oral fluid to test for antibodies to the HIV-1 virus, as well as cocaine and cotinine (an indicator of nicotine).
- Intercept® Oral Fluid Drug Testing System – the only FDA-cleared, laboratory-based oral fluid drug testing system currently on the market. Intercept® is an oral fluid drugs of abuse test that provides a smart alternative to costly, inconvenient and often embarrassing urine drug testing. This testing service detects the "NIDA-5" drug panel (marijuana, cocaine, opiates, PCP and amphetamines) plus barbiturates, methadone and benzodiazepines without the need to collect urine.

- Q.E.D.[®] Saliva Alcohol Test – an on-site, low-cost alternative to breath or blood testing for alcohol. The test is easy to administer and provides quantitative results as accurate as a blood test.

Cryosurgical Treatment Products

- Histofreezer[®] Portable Cryosurgical System – An FDA-cleared, low cost, highly effective cryosurgical system for the treatment of warts and a variety of other types of benign skin lesions.
- Compound W[®] Freeze Off[™] – An FDA-cleared, cryosurgical wart treatment product sold over-the-counter in the United States for the treatment of common and plantar warts.



Clients: OraSure Technologies' client base includes hospitals, public health agencies, physicians' offices, clinical laboratories, workplace sites, insurance companies and criminal justice facilities in the United States and abroad.

Other Locations: 150 Webster Street 1745 Eaton Avenue Fokkerstraat 112811
Bethlehem, PA 18015 Bethlehem, PA 18045 EN Reeuwijk
The Netherlands

Employees: 240

**Investor Relations
Contact:**

Ronald H. Spair, CFO
610-882-1820 ext. 3279
investorinfo@orasure.com

**Media
Contact:**

Jennifer Moritz
718-623-0355
Mobile – 917-748-4006
jmoritz@Oto5.com

Selected Financial Information:

	Six Months Ended June 30,	
	2006	2005
Revenues	\$ 32,781,739	\$ 33,258,472
Net income	\$ 2,107,865	\$ 3,004,014
Earnings per share -Basic	\$ 0.05	\$ 0.07
Earnings per share-Diluted	\$ 0.04	\$ 0.07
Number of shares-Basic	45,871,188	44,714,521
Number of shares-Diluted	47,944,152	45,433,765